Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CM-101

Monoclonal antibody · Antagonist of CCL24 (eotaxin-2) (CCL24) · developed by ChemomAb

Phase 2 Most advanced trial (none active)

CMMB Developer

2 Registered trials

What is CM-101?

CM-101 is an anti-human CCL24 monoclonal antibody given by intravenous infusion. It binds the chemokine CCL24, a soluble ligand, and is being studied in primary sclerosing cholangitis and nonalcoholic fatty liver disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: CCL24 (eotaxin-2) (CCL24)
Mechanism: Antagonist of CCL24 (eotaxin-2) (CCL24)
Therapy area: Gastroenterology
Developer: ChemomAb Ltd. (CMMB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 7SGW2C2ZH7

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04595825	Phase 2	Primary Sclerosing Cholangitis	Completed	CMMB
NCT06044467	Phase 1	Nonalcoholic Fatty Liver Disease	Completed	CMMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nonalcoholic Fatty Liver DiseasePrimary Sclerosing Cholangitis

Sources

ClinicalTrials.gov NCT04595825

Updated Oct 11, 2026. Something wrong or missing? Report it on the CMMB page.

Follow CMMB, the company behind CM-101

See CMMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMMB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z